Recobia Therapeutics
Recobia Therapeutics is developing a polysaccharide-based hydrogel platform that converts intravenous cancer biotherapies into subcutaneous formulations, enabling faster, more convenient administration. The biodegradable hydrogel supports high protein concentrations up to 200 mg/mL and provides controlled, tunable release of therapeutic proteins after injection. The technology aims to broaden patient access to advanced cancer treatments across a wider range of healthcare settings.
- Biotechnology
- Healthcare Technology
- New Materials
Funding
Founders
Founder details are not available yet.
Product
Problem
Advanced cancer biotherapies are predominantly administered intravenously, requiring lengthy infusion sessions that are inconvenient for patients and resource-intensive for hospitals. This delivery method limits patient access to cutting-edge treatments, particularly for those who face logistical challenges attending frequent clinic visits.
Solution
RecoBiaTx is developing a transition from intravenous to subcutaneous administration for cancer biotherapies, making these advanced treatments faster and more convenient to deliver. The company's proprietary platform uses a polysaccharide-based hydrogel that can be co-formulated with large proteins, including antibodies and antibody-drug conjugates, at high concentration. After subcutaneous injection, the hydrogel enables controlled release of the therapeutic protein. Subcutaneous injection significantly reduces administration time compared to IV infusion, easing the burden on hospital resources and improving the patient experience. This approach broadens access to cutting-edge cancer treatments by enabling administration in a wider range of healthcare settings, from hospitals to community clinics.
Target Audience
Primary customers are pharmaceutical companies seeking to reformulate existing IV biologics for subcutaneous delivery, as well as hospitals, oncology clinics, and healthcare providers looking for more efficient and patient-friendly methods of administering cancer biotherapies.
Features
- Polysaccharide-based biodegradable hydrogel platform designed to convert any intravenous protein formulation into a subcutaneous formulation
- Supports high protein concentrations up to 200 mg/mL, nearly 2x greater than standard subcutaneous formulations
- Compatible across various large proteins including antibodies and antibody-drug conjugates
- Controlled and tunable release of the therapeutic protein after injection
- Biocompatible formulation suitable for clinical use
- Reduced administration time and lower treatment costs for healthcare systems